Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Safety, tolerability, and clinical outcomes after intraarticular injection of a recombinant adeno-associated vector containing a tumor necrosis factor antagonist gene: results of a phase 1/2 Study.

Mease PJ, Wei N, Fudman EJ, Kivitz AJ, Schechtman J, Trapp RG, Hobbs KF, Greenwald M, Hou A, Bookbinder SA, Graham GE, Wiesenhutter CW, Willis L, Ruderman EM, Forstot JZ, Maricic MJ, Dao KH, Pritchard CH, Fiske DN, Burch FX, Prupas HM, Anklesaria P, Heald AE.

J Rheumatol. 2010 Apr;37(4):692-703. doi: 10.3899/jrheum.090817. Epub 2009 Dec 23.

PMID:
20032102
2.

The low-throughput protein A adsorber: an immune modulatory device. Hypothesis for the mechanism of action in the treatment of rheumatoid arthritis.

Brunner J, Kern PM, Gaipl US, Munoz LE, Voll RE, Kalden JR, Wiesenhutter CW, Herrmann M.

Mod Rheumatol. 2005;15(1):9-18.

PMID:
17028816
3.

Evaluation of the comparative efficacy of etoricoxib and ibuprofen for treatment of patients with osteoarthritis: A randomized, double-blind, placebo-controlled trial.

Wiesenhutter CW, Boice JA, Ko A, Sheldon EA, Murphy FT, Wittmer BA, Aversano ML, Reicin AS; Protocol 071 Study Group.

Mayo Clin Proc. 2005 Apr;80(4):470-9.

PMID:
15819283
4.

A randomized, double-blinded, placebo-controlled clinical trial of LY333013, a selective inhibitor of group II secretory phospholipase A2, in the treatment of rheumatoid arthritis.

Bradley JD, Dmitrienko AA, Kivitz AJ, Gluck OS, Weaver AL, Wiesenhutter C, Myers SL, Sides GD.

J Rheumatol. 2005 Mar;32(3):417-23.

PMID:
15742431
5.

Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study.

Furst DE, Saag K, Fleischmann MR, Sherrer Y, Block JA, Schnitzer T, Rutstein J, Baldassare A, Kaine J, Calabrese L, Dietz F, Sack M, Senter RG, Wiesenhutter C, Schiff M, Stein CM, Satoi Y, Matsumoto A, Caldwell J, Harris RE, Moreland LW, Hurd E, Yocum D, Stamler DA.

Arthritis Rheum. 2002 Aug;46(8):2020-8.

6.

Cevimeline for the treatment of xerostomia in patients with Sjögren syndrome: a randomized trial.

Fife RS, Chase WF, Dore RK, Wiesenhutter CW, Lockhart PB, Tindall E, Suen JY.

Arch Intern Med. 2002 Jun 10;162(11):1293-300.

PMID:
12038948
7.

CD4 coating, but not CD4 depletion, is a predictor of efficacy with primatized monoclonal anti-CD4 treatment of active rheumatoid arthritis.

Mason U, Aldrich J, Breedveld F, Davis CB, Elliott M, Jackson M, Jorgensen C, Keystone E, Levy R, Tesser J, Totoritis M, Truneh A, Weisman M, Wiesenhutter C, Yocum D, Zhu J.

J Rheumatol. 2002 Feb;29(2):220-9.

PMID:
11838838
8.

A pilot study using a staph protein A column (Prosorba) to treat refractory rheumatoid arthritis.

Caldwell J, Gendreau RM, Furst D, Wiesenhutter C, Quagliata F, Spindler J, Bertram J.

J Rheumatol. 1999 Aug;26(8):1657-62. Erratum in: J Rheumatol 1999 Dec;26(12):2718.

PMID:
10451058
9.
10.

Effects of administration of an anti-CD5 plus immunoconjugate in rheumatoid arthritis. Results of two phase II studies. The CD5 Plus Rheumatoid Arthritis Investigators Group.

Strand V, Lipsky PE, Cannon GW, Calabrese LH, Wiesenhutter C, Cohen SB, Olsen NJ, Lee ML, Lorenz TJ, Nelson B.

Arthritis Rheum. 1993 May;36(5):620-30.

PMID:
7683881
11.

IgG aggregates of different sizes stimulate or suppress Ig secretion by human lymphocytes in vitro.

Wiesenhutter C, Knutson DW, Musgrave DS, Ashman RF.

J Clin Immunol. 1984 Mar;4(2):124-33.

PMID:
6725532
12.

In vitro T lymphocyte proliferative response to Yersinia enterocolitica in Reiter's syndrome. Lack of response in other HLA-B27 positive individuals.

Brenner MB, Kobayashi S, Wiesenhutter CW, Huberman AK, Bales P, Yu DT.

Arthritis Rheum. 1984 Mar;27(3):250-7.

PMID:
6608353
13.

Panhypogammaglobulinemia in systemic lupus erythematosus: in vitro demonstration of multiple cellular defects.

Ashman RF, White RH, Wiesenhutter C, Cantor Y, Lasarow E, Liebling M, Talal N.

J Allergy Clin Immunol. 1982 Dec;70(6):465-73.

PMID:
6216277

Supplemental Content

Loading ...
Support Center